Rowland Lloyd A, General Counsel of CytomX Therapeutics Inc ($CTMX), sold shares once on the open market in the last year, totaling $6,112. His most recent sale occurred on March 18, 2025. These sales rank 11,370th among 11,678 insiders, compared to an average of $8.6 million per insider and 6.4 transactions. Rowland Lloyd A made no open market purchases in the period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 18, 2025 | CytomX Therapeutics, Inc. | $CTMX | ROWLAND LLOYD A | General Counsel | S | Common Stock | 10203 | $0.60 | 120,594.0000 | 80,099,889 | 7.80% | 0.01% |
| Aug. 20, 2024 | CytomX Therapeutics, Inc. | $CTMX | ROWLAND LLOYD A | General Counsel | M | Common Stock | 11250 | $0.00 | 134,978.0000 | 0 | 9.09% | 0.00% |
| Aug. 20, 2024 | CytomX Therapeutics, Inc. | $CTMX | ROWLAND LLOYD A | General Counsel | S | Common Stock | 4181 | $1.23 | 130,797.0000 | 0 | 3.10% | 0.00% |
| Aug. 20, 2024 | CytomX Therapeutics, Inc. | $CTMX | ROWLAND LLOYD A | General Counsel | M | Performance Stock Units (PSUs) | 11250 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| March 19, 2024 | CytomX Therapeutics, Inc. | $CTMX | ROWLAND LLOYD A | General Counsel | S | Common Stock | 5268 | $2.09 | 117,728.0000 | 0 | 4.28% | 0.00% |
| Jan. 18, 2024 | CytomX Therapeutics, Inc. | $CTMX | ROWLAND LLOYD A | General Counsel | A | Common Stock | 25000 | $0.00 | 122,996.0000 | 0 | 25.51% | 0.00% |
| Jan. 18, 2024 | CytomX Therapeutics, Inc. | $CTMX | ROWLAND LLOYD A | General Counsel | A | Stock Option (Right to Buy) | 100000 | $0.00 | 100,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 18, 2024 | CytomX Therapeutics, Inc. | $CTMX | ROWLAND LLOYD A | General Counsel | A | Performance Stock Units (PSUs) | 75000 | $0.00 | 75,000.0000 | 0 | 9999.99% | 0.00% |